Blood Culture Media Evaluated For Detection of Pathogenic Fungi
By LabMedica International staff writers Posted on 20 Jan 2015 |
A growing number of fungemia cases have been observed in recent decades and Candida species have been placed as the fourth most common microorganism isolated from blood samples.
Many cases of invasive mycoses, including invasive candidiasis, remain undiagnosed, mostly because of the insufficient sensitivity of blood cultures, which has been estimated as low as 50%. In order to improve the early diagnosis of invasive fungal diseases, several serological tests detecting fungal biomarkers, such as antigens, DNA, or specific antibodies, have been developed, of which only a few have gained acceptance for routine diagnostics.
Microbiologists at the Medical University of Wroclaw (Poland) compare the utility of different media in the detection of fungi from simulated tests obtained by the inoculation of tested media first with sterile sheep’s blood and subsequently with one of 60 clinical yeast isolates and clinical blood samples, taken during routine diagnostic examination in two hospitals.
The blood culture bottles BACTEC Mycosis-IC/F (Mycosis), BACTEC Plus Aerobic/F (Aerobic), and BACTEC Plus Anaerobic/F (Anaerobic) (BACTEC; Dartford, UK) were inoculated aseptically with sterile sheep’s blood and subsequently with of fungal suspension containing 10 to 20 fungal cells. The samples were immediately placed in the compartment of the BACTEC 9240 Blood Culture System (Becton, Dickinson and Company; Franklin Lakes, NJ, USA) and incubated until positivity, 5 days for Aerobic and Anaerobic, and 14 days for Mycosis.
All tested strains grew on Mycosis as well as Aerobic bottles, and the time to detection obtained for Mycosis was significantly shorter. The largest differences in the time to positivity were found for Candida glabrata and Cryptococcus neoformans, when Mycosis preceded Aerobic in 20 to 48 hours and 0.7 to 64 hours, respectively. The media complement each other and, in 45% of clinical examination sets, a single positive medium was noted with 25% in Mycosis and 19% in Aerobic.
The authors concluded that that both Aerobic and Mycosis media serve as the correct condition for the culture of fungi and that they varied significantly in the detection time of clinically important species. This result could suggest that the simultaneous use of Aerobic as well as Mycosis media may improve the time of diagnosis in many patients, especially those infected with C. glabrata or C. neoformans. The study was published in the January 2015 issue of the European Journal of Clinical Microbiology and Infectious Diseases.
Related Links:
Medical University of Wroclaw
BACTEC
Becton, Dickinson and Company
Many cases of invasive mycoses, including invasive candidiasis, remain undiagnosed, mostly because of the insufficient sensitivity of blood cultures, which has been estimated as low as 50%. In order to improve the early diagnosis of invasive fungal diseases, several serological tests detecting fungal biomarkers, such as antigens, DNA, or specific antibodies, have been developed, of which only a few have gained acceptance for routine diagnostics.
Microbiologists at the Medical University of Wroclaw (Poland) compare the utility of different media in the detection of fungi from simulated tests obtained by the inoculation of tested media first with sterile sheep’s blood and subsequently with one of 60 clinical yeast isolates and clinical blood samples, taken during routine diagnostic examination in two hospitals.
The blood culture bottles BACTEC Mycosis-IC/F (Mycosis), BACTEC Plus Aerobic/F (Aerobic), and BACTEC Plus Anaerobic/F (Anaerobic) (BACTEC; Dartford, UK) were inoculated aseptically with sterile sheep’s blood and subsequently with of fungal suspension containing 10 to 20 fungal cells. The samples were immediately placed in the compartment of the BACTEC 9240 Blood Culture System (Becton, Dickinson and Company; Franklin Lakes, NJ, USA) and incubated until positivity, 5 days for Aerobic and Anaerobic, and 14 days for Mycosis.
All tested strains grew on Mycosis as well as Aerobic bottles, and the time to detection obtained for Mycosis was significantly shorter. The largest differences in the time to positivity were found for Candida glabrata and Cryptococcus neoformans, when Mycosis preceded Aerobic in 20 to 48 hours and 0.7 to 64 hours, respectively. The media complement each other and, in 45% of clinical examination sets, a single positive medium was noted with 25% in Mycosis and 19% in Aerobic.
The authors concluded that that both Aerobic and Mycosis media serve as the correct condition for the culture of fungi and that they varied significantly in the detection time of clinically important species. This result could suggest that the simultaneous use of Aerobic as well as Mycosis media may improve the time of diagnosis in many patients, especially those infected with C. glabrata or C. neoformans. The study was published in the January 2015 issue of the European Journal of Clinical Microbiology and Infectious Diseases.
Related Links:
Medical University of Wroclaw
BACTEC
Becton, Dickinson and Company
Read the full article by registering today, it's FREE!

Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!

Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Microbiology News
- New Test Diagnoses Bacterial Meningitis Quickly and Accurately
- Handheld Device Delivers Low-Cost TB Results in Less Than One Hour
- New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
- Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
- Innovative ID/AST System to Help Diagnose Infectious Diseases and Combat AMR
- Gastrointestinal Panel Delivers Rapid Detection of Five Common Bacterial Pathogens for Outpatient Use
- Rapid PCR Testing in ICU Improves Antibiotic Stewardship
- Unique Genetic Signature Predicts Drug Resistance in Bacteria
- Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream
- Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
- Rapid Diagnostic System to Detect Neonatal Sepsis Within Hours
- Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood
- Interferon-γ Release Assay Effective in Patients with COPD Complicated with Pulmonary Tuberculosis
- New Point of Care Tests to Help Reduce Overuse of Antibiotics
- 30-Minute Sepsis Test Differentiates Bacterial Infections, Viral Infections, and Noninfectious Disease
- CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening
Channels
Clinical Chemistry
view channel
Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more
‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more
Low-Cost Portable Screening Test to Transform Kidney Disease Detection
Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more
New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
Cancer diagnoses have traditionally relied on invasive or time-consuming procedures like tissue biopsies. Now, new research published in ACS Central Science introduces a method that utilizes pulsed infrared... Read moreMolecular Diagnostics
view channel
Genetic-Based Tool Predicts Survival Outcomes of Pancreatic Cancer Patients
A tumor marker is a substance found in the body that may signal the presence of cancer. These substances, which can include proteins, genes, molecules, or other biological compounds, are either produced... Read more
Urine Test Diagnoses Early-Stage Prostate Cancer
Prostate cancer is one of the leading causes of death among men worldwide. A major challenge in diagnosing the disease is the absence of reliable biomarkers that can detect early-stage tumors.... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read morePathology
view channel
AI-Based Model Predicts Kidney Cancer Therapy Response
Each year, nearly 435,000 individuals are diagnosed with clear cell renal cell carcinoma (ccRCC), making it the most prevalent subtype of kidney cancer. When the disease spreads, anti-angiogenic therapies... Read more
Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation
Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read moreTechnology
view channel
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more